Real-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system

Simple item page
dc.contributor.authorGrassi, Bruno
dc.contributor.authorGomez, Ana Maria
dc.contributor.authorCalliari, Luis Eduardo
dc.contributor.authorFranco, Denise
dc.contributor.authorRaggio, Marcela
dc.contributor.authorRiera, Francisca
dc.contributor.authorCastro, Matias
dc.contributor.authorMcVean, Jennifer
dc.contributor.authorvan den Heuvel, Tim
dc.contributor.authorArrieta, Arcelia
dc.contributor.authorCastaneda, Javier
dc.contributor.authorCohen, Ohad
dc.date.accessioned2025-01-20T20:07:05Z
dc.date.available2025-01-20T20:07:05Z
dc.date.issued2023
dc.description.abstractAim: We studied real-world performance of MiniMed (MM) 780G system users from Argentina, Brazil, Colombia and Chile (geographical analysis), and the effect of each technology iteration of the MM system on glycaemic control (technology iteration analysis).Materials and Methods: CareLink data from August 2020 to September 2022 were extracted. Endpoints included continuous glucose monitoring metrics. For the geographical analysis, aggregated endpoints for MM780G system users were calculated. For the technology iteration analysis, MM780G system user outcomes were compared with outcomes when the same individuals were still using the MM640G or MM670G system.Results: On average, 1025 MM780G system users from the geographical analysis were followed for 136 (SD 135) days, spent 91.5 (14.3)% in advanced hybrid closed loop, showed a glucose management indicator (GMI) of 6.7 (0.3)%, a time in range between 70 and 180 mg/dl (TIR) of 76.5 (9.0)%, and a time below range 70 mg/dl (TBR) of 2.7 (2.1)%. The percentage of users reaching targets of GMI < 7%, TIR > 70% and TBR < 4% was 80.8%, 78.1% and 80.1%, respectively. The technology iteration analysis on users transitioning from MM640G to MM780G system (N = 381) showed 0.4% decrease in GMI (7.1% to 6.7%, p < .0001), 10.7% increase in TIR (65.9% to 76.6%, p < .0001), while TBR remained. The percentage of insulin delivered automatically increased as well (47.5%-57.7%, p < .0001). Users transitioning from MM670G system (N = 78) showed a similar but less pronounced pattern.Conclusions: Real-world Latin American MM780G users on average showed good glucose control, achieving international targets. Glycaemic control increased with every technology iteration of the MM system, providing more automation each time.
dc.description.funderMedtronic
dc.fuente.origenWOS
dc.identifier.doi10.1111/dom.15023
dc.identifier.eissn1463-1326
dc.identifier.issn1462-8902
dc.identifier.urihttps://doi.org/10.1111/dom.15023
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/91763
dc.identifier.wosidWOS:000948670300001
dc.issue.numero6
dc.language.isoen
dc.pagina.final1697
dc.pagina.inicio1688
dc.revistaDiabetes obesity & metabolism
dc.rightsacceso restringido
dc.subjecttype 1 diabetes
dc.subjectreal-world evidence
dc.subjectinsulin pump therapy
dc.subjectcontinuous glucose monitoring
dc.subjecthealth economics
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleReal-world performance of the MiniMed 780G advanced hybrid closed loop system in Latin America: Substantial improvement in glycaemic control with each technology iteration of the MiniMed automated insulin delivery system
dc.typeartículo
dc.volumen25
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas